Safeguard Scientifics Announces Life Sciences Advisory Board.

WAYNE, Pa. -- Safeguard Scientifics, Inc. (NYSE:SFE), today announced the initial meeting of its newly formed Life Sciences Advisory Board providing access to a select group of individuals with a broad range of strategic and operational knowledge and diverse expertise to assist specialty pharmaceutical, biotech, diagnostics and medical device companies introduce new products and services to help optimize their operations and accelerate growth. The Life Sciences Advisory Board is chartered with providing expert guidance and strategic direction for the benefit of Safeguard and its partner companies.

"We are delighted to assemble such a knowledgeable group of advisors as members of Safeguard's Life Sciences Advisory Board," said James A. Datin, Executive Vice President and Managing Director, Life Sciences at Safeguard Scientifics. "The Advisory Board provides a single source of knowledge and expertise relevant to emerging and small- to mid-sized life sciences companies. Our life sciences partner companies will benefit from their combined expertise."

"We anticipate that the newly established Life Sciences Advisory Board will work closely and interact with our newly established Information Technology Advisory Board," said Peter J. Boni, President and Chief Executive Officer of Safeguard. "Safeguard is utilizing the two Advisory Boards to augment our internal resources to achieve our vision of being the preferred catalyst for creating great information technology and life sciences companies."

The members of the newly formed Safeguard Life Sciences Advisory Board include:

--Pradip K. Banerjee, Ph.D., MBA - Dr. Banerjee has nearly 30 years of experience in the life sciences industry, both in the laboratory and in a consulting capacity. Today he is President and Chief Executive Officer of the University City Science Center in Philadelphia and a Managing Partner in Science Center Capital, a non-profit company with 32 universities in three states. Prior to joining the University City Science Center, Dr. Banerjee spent more than 15 years as a consultant to the life sciences industry providing strategic and operational R&D management consulting in genomics, bio-informatics, discovery, pre-clinical and clinical development and R&D IT activities for a number of major pharmaceutical companies.

--Edward L. Erickson - Mr. Erickson is chairman of the board of Immunicon Corporation, a publicly traded medical products company with advanced cell separation and analysis technology for use in diagnostics, pharmaceutical development and life-science research. With more than 20 years of experience in life sciences executive management, Mr. Erickson grew a publicly-traded biopharmaceutical company to more than 160 employees and closed two major corporate partnering deals. The IPO he completed in 1992 was one of the top 10 best performing Initial Public Offerings of that year.

--Mike Gausling - Mr. Gausling is Managing Partner with Blue Star Partners, LLC, a private equity investment company, and a member of the Board of Directors of KNBT Bancorp. He has proven success in guiding life sciences companies. As Chief Executive Officer of OraSure Technologies, he grew revenues 25 percent to $54 million, doubled the company's stock price and raised more than $50 million in a secondary offering. While at OraSure, he was recognized as Ernst & Young's Central/Eastern Pennsylvania Biotech Entrepreneur of the year.

--Matthew Malenfant - With more than 20 years of experience in sales and marketing in the life sciences industry, Matt is currently President, North American Lab Business, for VWR International, Inc., a global supplier of laboratory equipment. He is responsible for a $2 billion sales and operations entity serving the United States, Canada and Mexico. Matt has also developed new Centers of Excellence in Europe, launched a Global Sourcing Team with personnel in China and India, and he formed a service division that generated more than $300 million in sales.

--Jeffrey F. O'Donnell - Mr. O'Donnell joined PhotoMedex in 1999 as President and CEO and serves as Directors since that date. Prior to PhotoMedex, he joined Radiance Medical Systems as Vice President of Sales and Marketing and was promoted to President and CEO. Previously, Mr. O'Donnell held the position of President and CEO of Kensey Nash Corporation, a manufacturer of cardiology products. Additionally, he has held several senior sales and marketing management positions at Boston Scientific, Guidant and Johnson & Johnson Orthopedic.

--Christopher Simon - Mr. Simon leads the North American Pharmaceutical Sales and Marketing Group for McKinsey & Company. He also is a director in the consulting firm's Philadelphia office. He has considerable experience in addressing strategic and operational issues for a range of pharmaceutical, biotech and medical device manufacturers and diversified health care services companies.

--Mark S. Speers - Mark is Managing Director of Health Advances, LLC, a strategy consulting firm focusing on assisting medical device, diagnostics and biopharmaceutical companies. He co-founded the firm in 1992 after gaining 10 years of international strategy consulting experience in the healthcare industry. Over the last 14 years, he has primarily focused on evaluating the commercial potential and/or developing market launch strategies for new medical devices and diagnostics. In addition, he was involved in fund-raising and several mergers and acquisitions.

About Safeguard

Safeguard Scientifics, Inc. (NYSE:SFE) builds value in high-growth, revenue-stage information technology and life sciences businesses. We provide growth capital as well as a range of strategic, operational and management resources to our partner companies. Safeguard participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. For more information about Safeguard and its strategy, visit www.safeguard.com.

Forward-Looking and Cautionary Statements

Except for the historical information and discussions contained herein, statements contained in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Our forward-looking statements are subject to risks and uncertainties. These forward-looking statements that could cause actual results to differ materially, include, among others, managing rapidly changing technologies, limited access to capital, competition, the ability to attract and retain qualified employees, the ability to execute our strategy, the uncertainty of the future performance of our companies, acquisitions and dispositions of companies, the inability to manage growth, compliance with government regulations and legal liabilities, additional financing requirements, labor disputes, the effect of economic conditions in the business sectors in which our companies operate, and other uncertainties described in the Company's filings with the Securities and Exchange Commission. Many of these factors are beyond our ability to predict or control. In addition, as a result of these and other factors, our past financial performance should not be relied on as an indication of future performance. The Company does not assume any obligation to update any forward-looking statements or other information contained in this press release.